KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2025)

Historic Convertible Debt for Pacific Biosciences Of California (PACB) over the last 5 years, with Q3 2025 value amounting to $645.2 million.

  • Pacific Biosciences Of California's Convertible Debt fell 2776.54% to $645.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.2 million, marking a year-over-year decrease of 2776.54%. This contributed to the annual value of $647.5 million for FY2024, which is 2743.08% down from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Convertible Debt is $645.2 million, which was down 2776.54% from $646.4 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Convertible Debt peaked at $896.8 million during Q1 2023, and registered a low of $645.2 million during Q3 2025.
  • Its 5-year average for Convertible Debt is $842.4 million, with a median of $893.1 million in 2024.
  • Per our database at Business Quant, Pacific Biosciences Of California's Convertible Debt grew by 12.87% in 2024 and then tumbled by 2776.54% in 2025.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Convertible Debt stood at $896.1 million in 2021, then rose by 0.07% to $896.7 million in 2022, then decreased by 0.5% to $892.2 million in 2023, then dropped by 27.43% to $647.5 million in 2024, then fell by 0.36% to $645.2 million in 2025.
  • Its Convertible Debt was $645.2 million in Q3 2025, compared to $646.4 million in Q2 2025 and $646.2 million in Q1 2025.